Use of Fast Gamma Magnetic Stimulation Over the Left Prefrontal Dorsolateral Cortex for the Treatment of MCI and Mild Alzheimer's Disease: A Double-Blind, Randomized, Sham-Controlled, Pilot Study
Overview
Authors
Affiliations
Alzheimer's disease (AD) animal models have shown a reduced gamma power in several brain areas, and induction of these oscillations by non-invasive methods has been shown to modify several pathogenic mechanisms of AD. In humans, the application of low-intensity magnetic fields has shown to be able to produce neural entrainment at the magnetic pulse frequency, making it useful to induce gamma frequencies. The aim of this study was to assess if the application of fast gamma magnetic stimulation (FGMS) over the left prefrontal dorsolateral cortex would be a safe and well-tolerated intervention that could potentially improve cognitive scores in subjects with mild cognitive impairment and mild AD. In these randomized, double-blind, sham-controlled study, participants were assigned to either receive daily sessions two times a day of active or sham FGMS for 6 months. Afterward, measurements of adverse effects, cognition, functionality, and depression were taken. Thirty-four patients, 17 in each group, were analyzed for the primary outcome. FGMS was adequately tolerated by most of the subjects. Only four patients from the active FGMS group (23.52%) and one patient from the sham FGMS group (5.88%) presented any kind of adverse effects, showing no significant difference between groups. Nevertheless, FGMS did not significantly change cognitive, functionality, or depressive evaluations. FGMS over the left prefrontal dorsolateral cortex applied twice a day for 6 months resulted to be a viable intervention that can be applied safely directly from home without supervision of a healthcare provider. However, no statistically significant changes in cognitive, functionality, or depression scores compared to sham stimulation were observed. www.ClinicalTrials.gov, Identifier: NCT03983655, URL: https://clinicaltrials.gov/ct2/show/NCT03983655.
A Focused Review of Gamma Neuromodulation as a Therapeutic Target in Alzheimer's Spectrum Disorders.
Shu I, Lin Y, Granholm E, Singh F J Psychiatr Brain Sci. 2024; 9(1).
PMID: 38550308 PMC: 10976397. DOI: 10.20900/jpbs.20240001.
The role of gamma oscillations in central nervous system diseases: Mechanism and treatment.
Guan A, Wang S, Huang A, Qiu C, Li Y, Li X Front Cell Neurosci. 2022; 16:962957.
PMID: 35966207 PMC: 9374274. DOI: 10.3389/fncel.2022.962957.
Jiang Y, Jessee W, Hoyng S, Borhani S, Liu Z, Zhao X Front Aging Neurosci. 2022; 14:780817.
PMID: 35418848 PMC: 8995767. DOI: 10.3389/fnagi.2022.780817.
Can gamma entrainment of the brain rhythms prevent or alleviate Alzheimer's disease?.
Kim T J Transl Int Med. 2022; 9(4):231-233.
PMID: 35136721 PMC: 8802396. DOI: 10.2478/jtim-2021-0048.